化合物 T14831
化合物 T14831 性质
| 熔点 | 230-235° |
|---|---|
| 比旋光度 | D25 +34.1° (c = 0.044 in methanol) |
| 沸点 | 716.44°C (rough estimate) |
| 密度 | 1.1245 (rough estimate) |
| 折射率 | 1.5940 (estimate) |
| 储存条件 | -20°C |
| 溶解度 | 可溶于DMSO |
| 酸度系数(pKa) | 11.10±0.70(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色 |
| 旋光度 (Optical Rotation) | +34.125 (methanol) |
| InChIKey | MJQUEDHRCUIRLF-TVIXENOKSA-N |
化合物 T14831 用途与合成方法
PKC
HIV-1
Bryostatin 1 (1 µM; 5 minutes; HT22 cells) treatment successfully recruits Munc13-1 from the cytosol to the plasma membrane. Effects of Bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation .
The increased level of expression of Munc13-1 following a 24 h incubation with Bryostatin 1 in both HT22 and primary mouse hippocampal cells is observed.
Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) via toll-like receptor 4 (TLR4) through the MyD88-independent pathway, which favors an anti-inflammatory environment by inducing a type 2 phenotype that promotes the differentiation of CD4
+
T-helper (Th) lymphocytes into Th2 versus Th1 effector cells.
Western Blot Analysis
| Cell Line: | HT22 cells |
| Concentration: | 1 µM |
| Incubation Time: | 5 minutes |
| Result: | Caused Munc13-1 to transfer to the membrane fraction. |
Bryostatin 1 (30 μg/kg; intraperitoneal injection; 3 d per week; for 2 weeks; C57BL/6J mice) treatment abolishes the onset of EAE.
| Animal Model: | Female C57BL/6J mice (8-12-week-old) with MOG 35-55 |
| Dosage: | 30 μg/kg |
| Administration: | Intraperitoneal injection; 3 d per week; for 2 weeks |
| Result: | Abolished the onset of experimental autoimmune encephalomyelitis (EAE). |
安全信息
| 危险品标志 | Xn |
|---|---|
| 危险类别码 | 68 |
| 安全说明 | 22-24/25-36/37 |
| WGK Germany | 3 |
| RTECS号 | EH9455000 |
| 海关编码 | 2932990090 |
| 存储类别 | 11 - 可燃固体 |
| 毒性 | LD50 in mice, rats (mg/kg): 0.038, 0.068 i.v. (Prendiville) |
